thalidomide has been researched along with Hyponatremia in 3 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Hyponatremia: Deficiency of sodium in the blood; salt depletion. (Dorland, 27th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 9.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM)." | 5.62 | Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. ( Qureshi, A; Rhee, JH, 2021) |
| "Panobinostat 20 mg in combination with bortezomib, thalidomide, and dexamethasone is an efficacious and well tolerated regimen for patients with relapsed multiple myeloma." | 5.22 | Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial. ( Brown, SR; Cavenagh, J; Cook, G; Flanagan, L; Gregory, W; Hall, A; Kishore, B; Low, E; Oakervee, H; Popat, R; Streetly, M; Yong, K, 2016) |
| "Pomalidomide is an immunomodulatory drug used for relapsed and refractory multiple myeloma (RRMM)." | 1.62 | Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide. ( Qureshi, A; Rhee, JH, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Qureshi, A | 1 |
| Rhee, JH | 1 |
| Nakazato, T | 1 |
| Hagihara, M | 1 |
| Sahara, N | 1 |
| Tamai, Y | 1 |
| Ishii, R | 1 |
| Tamaki, S | 1 |
| Wake, A | 1 |
| Tajika, K | 1 |
| Sakai, R | 1 |
| Kobayashi, T | 1 |
| Hua, J | 1 |
| Inoue, M | 1 |
| Aisa, Y | 1 |
| Fujisawa, S | 1 |
| Miyazaki, K | 1 |
| Irie, S | 1 |
| Tanaka, E | 1 |
| Higashihara, M | 1 |
| Popat, R | 1 |
| Brown, SR | 1 |
| Flanagan, L | 1 |
| Hall, A | 1 |
| Gregory, W | 1 |
| Kishore, B | 1 |
| Streetly, M | 1 |
| Oakervee, H | 1 |
| Yong, K | 1 |
| Cook, G | 1 |
| Low, E | 1 |
| Cavenagh, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/IIa Trial of VTD-panobinostat Treatment and Panobinostat Maintenance in Relapsed and Relapsed/Refractory Multiple Myeloma Patients[NCT02145715] | Phase 1/Phase 2 | 54 participants (Anticipated) | Interventional | 2013-01-31 | Active, not recruiting | ||
| A Prospective, Multicenter, Single Arm, Phase II Clinical Trial of Clarithromycin, Lenalidomide and Dexamethasone (BiRd Regimen) in the Treatment of the First Relapsed Multiple Myeloma[NCT04063189] | Phase 2 | 100 participants (Anticipated) | Interventional | 2017-03-21 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for thalidomide and Hyponatremia
| Article | Year |
|---|---|
Phase II clinical trial of personalized VCD-VTD sequential therapy using the Vulnerable Elders Survey-13 (VES-13) for transplant-ineligible patients with newly diagnosed multiple myeloma.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamid | 2021 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
Bortezomib, thalidomide, dexamethasone, and panobinostat for patients with relapsed multiple myeloma (MUK-six): a multicentre, open-label, phase 1/2 trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Constipation; Dexamethasone; Diarr | 2016 |
1 other study available for thalidomide and Hyponatremia
| Article | Year |
|---|---|
Hyponatraemia due to hypothyroidism: a rare side effect from pomalidomide.
Topics: Aged; Humans; Hyponatremia; Hypothyroidism; Male; Thalidomide; Thyrotropin; Thyroxine; Triiodothyron | 2021 |